Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:956-962
Published online before print March 19, 2009, doi: 10.1161/ATVBAHA.109.186577
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
29/6/956    most recent
ATVBAHA.109.186577v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Beigneux, A. P.
Right arrow Articles by Young, S. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beigneux, A. P.
Right arrow Articles by Young, S. G.
Related Collections
Right arrow Clinical genetics
Right arrow Lipid and lipoprotein metabolism
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:956.)
© 2009 American Heart Association, Inc.


Clinical and Population Studies

Chylomicronemia With a Mutant GPIHBP1 (Q115P) That Cannot Bind Lipoprotein Lipase

Anne P. Beigneux; Remco Franssen; André Bensadoun; Peter Gin; Kristan Melford; Jorge Peter; Rosemary L. Walzem; Michael M. Weinstein; Brandon S.J. Davies; Jan A. Kuivenhoven; John J.P. Kastelein; Loren G. Fong; Geesje M. Dallinga-Thie; Stephen G. Young

From the Departments of Medicine (A.P.B., P.G., B.S.J.D., M.M.W., L.G.F., S.G.Y.) and Human Genetics (M.M.W., S.G.Y.), David Geffen School of Medicine, University of California, Los Angeles; the Department of Vascular Medicine (R.F., J.J.K.) and the Laboratory of Experimental Vascular Medicine (G.D.T., J.P., J.A.K.), Amsterdam Medical Center, The Netherlands; the Division of Nutritional Science (K.M., A.B.), Cornell University, Ithaca, NY; and Departments of Poultry Science and Nutrition and Food Science (R.L.W.), Texas A&M University, College Station.

Correspondence to Anne P. Beigneux, 675 Charles E. Young Dr South, Los Angeles, CA 90095. E-mail abeigneux{at}mednet.ucla.edu and Geesje Dallinga-Thie, Laboratory of Experimental Vascular Medicine G1-113. AMC, Amsterdam, The Netherlands. E-mail g.m.dallinga@ame.nl

Objective— GPIHBP1 is an endothelial cell protein that binds lipoprotein lipase (LPL) and chylomicrons. Because GPIHBP1 deficiency causes chylomicronemia in mice, we sought to determine whether some cases of chylomicronemia in humans could be attributable to defective GPIHBP1 proteins.

Methods and Results— Patients with severe hypertriglyceridemia (n=60, with plasma triglycerides above the 95th percentile for age and gender) were screened for mutations in GPIHBP1. A homozygous GPIHBP1 mutation (c.344A>C) that changed a highly conserved glutamine at residue 115 to a proline (p.Q115P) was identified in a 33-year-old male with lifelong chylomicronemia. The patient had failure-to-thrive as a child but had no history of pancreatitis. He had no mutations in LPL, APOA5, or APOC2. The Q115P substitution did not affect the ability of GPIHBP1 to reach the cell surface. However, unlike wild-type GPIHBP1, GPIHBP1-Q115P lacked the ability to bind LPL or chylomicrons (d < 1.006 g/mL lipoproteins from Gpihbp1–/– mice). Mouse GPIHBP1 with the corresponding mutation (Q114P) also could not bind LPL.

Conclusions— A homozygous missense mutation in GPIHBP1 (Q115P) was identified in a patient with chylomicronemia. The mutation eliminated the ability of GPIHBP1 to bind LPL and chylomicrons, strongly suggesting that it caused the patient’s chylomicronemia.

A homozygous missense mutation in GPIHBP1 (Q115P) was identified in a 33-year-old male with lifelong chylomicronemia. The mutant GPIHBP1 lacked the ability to bind lipoprotein lipase or chylomicrons, suggesting that the Q115P mutation is functionally important and underlies the patient’s chylomicronemia.


Key Words: lipoprotein • lipase • human • chylomicronemia • hypertriglyceridemia • GPIHBP1


Related Article:

Some Things Just Have to Be Done In Vivo: GPIHBP1, Caloric Delivery, and the Generation of Remnant Lipoproteins
Kevin Jon Williams
Arterioscler Thromb Vasc Biol 2009 29: 792-795. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Lipid Res.Home page
W. K. Sonnenburg, D. Yu, E-C. Lee, W. Xiong, G. Gololobov, B. Key, J. Gay, N. Wilganowski, Y. Hu, S. Zhao, et al.
GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4
J. Lipid Res., December 1, 2009; 50(12): 2421 - 2429.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. B. Cefalu, D. Noto, M. L. Arpi, F. Yin, R. Spina, H. Hilden, C. M. Barbagallo, A. Carroccio, P. Tarugi, S. Squatrito, et al.
Novel LMF1 Nonsense Mutation in a Patient with Severe Hypertriglyceridemia
J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4584 - 4590.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. P. Beigneux, P. Gin, B. S. J. Davies, M. M. Weinstein, A. Bensadoun, L. G. Fong, and S. G. Young
Highly Conserved Cysteines within the Ly6 Domain of GPIHBP1 Are Crucial for the Binding of Lipoprotein Lipase
J. Biol. Chem., October 30, 2009; 284(44): 30240 - 30247.
[Abstract] [Full Text] [PDF]